Phase II study of topotecan and cisplatin for elderly small-cell lung cancer

Phase II study of topotecan and cisplatin for elderly small-cell lung cancer - Phase II study of topotecan and cisplatin for elderly small-cell lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000134

Enrollment

Registered

2005-09-12

Start date

2004-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly small-cell lung cancer

Interventions

Combination chemotherapy of topotecan and cisplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically and/or cytologically proven SCLC No prior surgery, chemotherapy, or radiotherapy Age ≥76 ECOG performance status 0, 1 or 2 Measurable disease adequate bone marrow, lung, hepatic, and renal function Written informed consent

Exclusion criteria

Exclusion criteria: Active concomitant malignancy Active interstitial pneumonia Massive effusions Unstable angina, recent myocardial infarction Uncontrolled diabetes Symptomatic brain metastasis Severe active infection Other severe complications Inappropriate condition for this study judged by physicians.

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Adverse events, overall survival, 1-year survival rate	—

Countries

Japan

Contacts

Public ContactNagio Takigawa

Okayama Lung Cancer Study Group Coordinating Office Okayama University Hospital, Respiratory Medicine

ntakigaw@md.okayama-u.ac.jp086-235-7227

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026